Introduction :
The phenomenon of ‘stem cell tourism,’ in which patients travel to foreign countries to undergo supposed stem cell-based treatments in unregulated settings has been recognized as a problem for years. More recently, however, companies marketing such stem cell products of unknown efficacy have begun to operate openly in countries such as the USA, Australia, and Japan. We will examine the ethical, legal, social, and economic implications of regulation and regulatory failure in stem cell marketing. Our ultimate goal is to seek to understand drivers and reach a consensus on concise guidelines that might serve to impede the proliferation of quasi-therapeutics which make premature claims of efficacy.
Partager cet événement